Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.



Dickinson, Laura ORCID: 0000-0001-5557-9396, Amin, J, Else, Laura, Boffito, M, Egan, Deirdre, Owen, Andrew ORCID: 0000-0002-9819-7651, Khoo, Saye, Back, David, Orrell, C, Clarke, A
et al (show 6 more authors) (2015) Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study. Clinical pharmacology and therapeutics, 98 (4). 406 - 416.

[img] Text
Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.pdf - OA Published Version

Download (698kB)

Abstract

Daily efavirenz 400 mg (EFV400) was virologically noninferior to 600 mg (EFV600) at 48 weeks in treatment-naïve patients. We evaluated EFV400 and EFV600 pharmacokinetics (NONMEM v. 7.2), assessing patient demographics and genetic polymorphisms (CYP2B6, CYP2A6, CYP3A4, NR1I3) as covariates and explored relationships with efficacy (plasma HIV-RNA (pVL) T/983T>C/CYP2A6*9B/*17 and weight were associated with efavirenz CL/F. Exposure was significantly lower for EFV400 (geometric mean ratio, GMR; 90% confidence interval, CI: 0.73 (0.68-0.78)) but 97% (EFV400) and 98% (EFV600) of evaluable pVL was

Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 13 Jul 2018 15:03
Last Modified: 21 Apr 2021 16:10
DOI: 10.1002/cpt.156
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3023732